CLINICAL TRIALS PROFILE FOR BEVACIZUMAB

Biosimilar Clinical Trials for bevacizumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Laboratorio Elea Phoenix S.A.	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Laboratorio Elea S.A.C.I.F. y A.	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Libbs Farmacêutica LTDA	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	mAbxience S.A	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02450981 ↗	Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration	Withdrawn	Biocad	Phase 1	1969-12-31	This clinical study is a phase 1 study which carried out to to evaluate the safety, pharmacokinetics and tolerability of multiple intravitreal injections of BCD-021(bevacizumab biosimilar candidate manufactured by CJSC BIOCAD, Russia) when used in patients with neovascular wet age-related macular degeneration.
NCT02754882 ↗	A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer	Completed	Samsung Bioepis Co., Ltd.	Phase 3	2016-07-05	This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
NCT02879097 ↗	Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC	Unknown status	Cipla BioTec Pvt. Ltd.	Phase 3	2016-12-01	The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients).

All Clinical Trials for bevacizumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006786 ↗	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-11-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bevacizumab in treating patients who have advanced colorectal cancer.
NCT00006786 ↗	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer	Completed	Eastern Cooperative Oncology Group	Phase 2	2000-11-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bevacizumab in treating patients who have advanced colorectal cancer.
NCT00015951 ↗	Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	Completed	National Cancer Institute (NCI)	Phase 2	2001-04-01	RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
NCT00015951 ↗	Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	Completed	University of Maryland Greenebaum Cancer Center	Phase 2	2001-04-01	RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
NCT00015951 ↗	Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	Completed	University of Maryland	Phase 2	2001-04-01	RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
NCT00015951 ↗	Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	Completed	University of Maryland, Baltimore	Phase 2	2001-04-01	RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
NCT00016107 ↗	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-06-01	Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.

Clinical Trial Conditions for bevacizumab

Condition Name

Condition Name for bevacizumab
Intervention	Trials
Colorectal Cancer	246
Metastatic Colorectal Cancer	146
Breast Cancer	137
Ovarian Cancer	119

Condition MeSH

Condition MeSH for bevacizumab
Intervention	Trials
Colorectal Neoplasms	582
Carcinoma, Non-Small-Cell Lung	289
Carcinoma	277
Lung Neoplasms	266

Clinical Trial Locations for bevacizumab

Trials by Country

Trials by Country for bevacizumab
Location	Trials
United States	7,782
China	670
Italy	634
Spain	512
Japan	396

Trials by US State

Trials by US State for bevacizumab
Location	Trials
California	418
Texas	370
New York	325
Florida	305
Ohio	302

Clinical Trial Progress for bevacizumab

Clinical Trial Phase

Clinical Trial Phase for bevacizumab
Clinical Trial Phase	Trials
PHASE4	13
PHASE3	44
PHASE2	230

Clinical Trial Status

Clinical Trial Status for bevacizumab
Clinical Trial Phase	Trials
Completed	1145
Recruiting	576
Terminated	234

Clinical Trial Sponsors for bevacizumab

Sponsor Name

Sponsor Name for bevacizumab
Sponsor	Trials
Genentech, Inc.	335
National Cancer Institute (NCI)	324
Hoffmann-La Roche	193

Sponsor Type

Sponsor Type for bevacizumab
Sponsor	Trials
Other	2974
Industry	1560
NIH	342

Bevacizumab Clinical Trials Update and Market Analysis (2026 Outlook)

Last updated: April 23, 2026

What is bevacizumab and what is it used for?

Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A). It is used to treat multiple solid tumors, primarily in combination with chemotherapy or other regimens, across colorectal, lung, breast, renal, cervical, and ovarian cancers.

What does the clinical trial landscape look like in 2024-2026?

Bevacizumab is widely tested in combination strategies and in new biomarker or dosing frameworks. Trials span:

• Earlier-stage disease settings (adjuvant/neoadjuvant and perioperative)
• Expanded biomarker strategies (tumor and circulating markers)
• Combination regimens with checkpoint inhibitors, targeted therapies, and different chemotherapy backbones

Trial pattern by program type (2024-2026 focus)

Program type	Typical objective	Common design signals in registries	Practical implication
Combination with immunotherapy	Increase response rate and durability through VEGF pathway normalization	Phase 2/3 in NSCLC, CRC, GU tumors	Ongoing label expansion and sequencing questions
Perioperative and earlier-stage use	Reduce micrometastatic disease and recurrence risk	Studies in resectable disease cohorts	Lower event-time reduces readout cycles; regulatory leverage
Biomarker-enriched cohorts	Identify responders and optimize patient selection	Studies using tissue/circulating markers, histology subclasses	Drives health economics and payer acceptance
Dose and schedule refinement	Improve tolerability and maintain efficacy	Trials comparing dosing intervals/schedules	Reduces discontinuation-related waste

Key practical reality: bevacizumab is an “in-class backbone” for VEGF-A blockade, so most new readouts cluster in combination optimization rather than first-in-class MoA discovery.

Which bevacizumab clinical themes are most likely to move markets?

Market-moving outcomes typically require one of three things: (1) label expansion into a large addressable indication, (2) a new standard-of-care combo with survival endpoints, or (3) evidence that reduces discontinuation or adds strong biomarker selection.

The most market-relevant trial themes are:

• Checkpoint inhibitor plus bevacizumab regimens that demonstrate durable OS benefit or strong progression-free survival (PFS) with acceptable safety
• Earlier-stage colorectal and lung perioperative approaches aiming to move recurrence endpoints
• Biomarker-driven patient selection that improves benefit-to-risk and supports payer coverage

How is the bevacizumab R&D pipeline positioned versus biosimilar penetration?

The R&D stance for bevacizumab in 2024-2026 is less about new monotherapy breakthroughs and more about:

• Sustaining differentiating clinical value through combination frameworks
• Supporting payer adoption by tightening patient selection and managing safety
• Extending clinical credibility across lines of therapy

With biosimilars, clinical differentiation often shifts from brand-level efficacy to:

• Specific evidence for the brand in high-priority combinations
• Practical safety management, particularly hypertension, proteinuria, bleeding, and thromboembolic risks

Who controls the competitive landscape?

Bevacizumab competes with:

• Biosimilars of bevacizumab across major markets
• Alternative VEGF/VEGF receptor pathway inhibitors (in certain settings)
• Different anti-angiogenic strategies combined with immunotherapy or targeted agents

What is the current market structure for bevacizumab?

Bevacizumab’s global market is driven by:

• Large prevalence solid tumors (mCRC, NSCLC, renal cell carcinoma, ovarian cancer, cervical cancer)
• High utilization in combination regimens
• Post-expiry dynamics that shift volume to biosimilars

Market structure by product category

Segment	Economic driver	Typical buyer behavior	Competitive impact
Reference (originator) bevacizumab	Clinical familiarity and guideline inclusion	Institutional formularies, tendering	Protected by evidence in specific combo pathways
Biosimilars	Acquisition cost and budget impact	Switching to lowest-cost equivalent	Compresses net pricing across geographies
Competitive MoA (anti-angiogenic or combo oncology)	Indication-specific efficacy	Treatment sequencing and guideline updates	Takes share where outcomes outperform or simplify regimens

What does pricing pressure imply for revenue in 2024-2026?

The historical pattern for bevacizumab in major markets has been:

• Net price declines after biosimilar entry
• Continued volume growth is offset by declining net revenue per dose
• Mix shifts toward lower-cost products

For forecasting, the central driver is not whether physicians use bevacizumab, but how much net revenue is captured after biosimilar penetration in each region.

Market forecast: base case through 2027 (directional projections)

Because bevacizumab is mature and biosimilars dominate in many markets, projections are best expressed in terms of net revenue pressure plus stable-to-moderate volume.

Regional projection framework (base case)

Region	Expected biosimilar intensity	Revenue direction (2024-2027)	Key assumption
US	High	Modest decline to flat net revenue	Rapid switching and tender pressure; stable core indications
EU5	High	Mid-single-digit decline then stabilization	Market competition and formulary steering stabilize later
Japan	Moderate	Decline then stabilization	Slower switching relative to Western markets
China	Increasing	Growth in volumes but price erosion	Growing oncology base with pricing compression

How do clinical outcomes translate into share gains versus biosimilars?

Biosimilars constrain revenue capture, so share gains depend on:

• Evidence that a specific combination improves OS or creates a clear sequencing advantage
• Guideline inclusion and uptake speed after positive trials
• Safety handling that reduces discontinuation and supports continuation therapy

Value chain reality

• If new trials reinforce bevacizumab’s role in first-line or perioperative regimens, utilization stays high even when price drops.
• If new regimens shift practice to alternative VEGF pathways or different partners with stronger endpoints, bevacizumab share can fall faster than volume totals.

What are the biggest risks to bullish forecasts for bevacizumab?

1. Treatment sequencing shifts driven by newer standards that replace bevacizumab combos in large cohorts.
2. Safety and discontinuation rates in expanded settings, which can reduce achievable dose intensity.
3. Payer formulary changes that prioritize lower-cost biosimilars or alternative agents.
4. Competitive efficacy: if another anti-angiogenic option plus immunotherapy demonstrates superior OS/PFS in head-to-head or pragmatic studies.

What are the primary tailwinds?

1. Large guideline-covered tumor categories where bevacizumab is entrenched.
2. Combination data that expands use with high-uptake regimens (especially immunotherapy partnerships).
3. Biomarker refinement improving responder rates, which can support broader coverage and sustained utilization.
4. Institutional practice and entrenched pathways that reduce switching friction.

---

What do recent regulatory and evidence sources say about bevacizumab’s status?

Bevacizumab remains a well-established oncology therapy with ongoing labeling and evidence support across multiple tumor types. Reference guidance on use comes from major oncology references and regulatory summaries.

Key reference sources:

• FDA labeling and prescribing information for Avastin (reference bevacizumab) [1]
• Clinical trial registry information on ongoing studies (Trials and registration data) [2]
• WHO ATC classification for bevacizumab in the oncology/biologics framework [3]

---

Market projection summary (2024-2027)

Base-case projection (directional)

• Global volume: stable to modest growth supported by standard-of-care placement and combination strategies.
• Net revenue: declines driven by biosimilar switching and pricing compression; stabilization in later years as markets mature.
• Originator share: constrained by biosimilar competition, but can remain resilient in specific high-evidence combinations and institutions with stricter reference product usage.

Range view (planning bands)

Metric	Downside	Base case	Upside
Global net revenue CAGR (2024-2027)	-6%	-2% to -3%	0% to -1%
Originator share	Steeper erosion	Gradual erosion	Slower erosion via evidence-driven combo stickiness
Utilization in top indications	Flat to declining	Flat with slight mix shift	Slight growth from label expansion

---

Key Takeaways

• Bevacizumab’s 2024-2026 clinical activity is dominated by combination optimization and earlier-stage / biomarker-enriched strategies, not new monotherapy breakthroughs.
• The market outlook is shaped by biosimilar-driven pricing pressure, which makes net revenue projections sensitive to regional switching intensity.
• The most market-relevant clinical outcomes are those that expand into high-enrollment standards or lock in bevacizumab within immunotherapy- and perioperative regimens.
• Forecasts through 2027 are best framed as stable utilization with declining net revenue, followed by stabilization as biosimilar markets mature.

FAQs

1) What is the main factor reducing bevacizumab revenues?

Biosimilar entry and formulary switching that compress net pricing.

2) Does ongoing R&D change the market if biosimilars are already widely used?

Yes, if new trial outcomes expand bevacizumab into new high-enrollment regimens or strengthen evidence for a specific standard-of-care combination where physicians and guidelines maintain consistent use.

3) Which clinical themes are most likely to influence practice?

Checkpoint inhibitor combinations, perioperative use in resectable disease, and biomarker-driven patient selection that improves outcomes and tolerability.

4) Are risks mainly clinical or commercial?

Both. Clinical risks include safety and discontinuation in expanded settings; commercial risks include payer-driven substitution and alternative regimen standards.

5) What is the most realistic 2024-2027 direction for net revenue?

Net revenue is expected to decline globally in the base case, then stabilize as biosimilar markets mature and mix stabilizes.

---

References

[1] U.S. Food and Drug Administration. (n.d.). AVASTIN (bevacizumab) prescribing information. FDA.
[2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Bevacizumab studies. ClinicalTrials.gov.
[3] World Health Organization. (n.d.). ATC/DDD index: Bevacizumab. WHO Collaborating Centre for Drug Statistics Methodology.